Christopher J. Mee

Christopher J. Mee

Auto-generated profile, based on publicly available information

Christopher J. Mee

Hepatitis C Research Group, Institute for Biomedical Research, University of Birmingham, Birmingham, United Kingdom

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2011 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
JLJoachim Lupberger
Joachim Lupberger
MZMirjam B Zeisel
Mirjam B Zeisel
FXFei Xiao
Fei Xiao
CTChristine Thumann
Christine Thumann
IFIsabel Fofana
Isabel Fofana
TBThomas Baumert
Thomas Baumert

1 July 2010 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
HHHelen J. Harris
Helen J. Harris
CDChristopher Davis
Christopher Davis
JMJonathan G. L. Mullins
Jonathan G. L. Mullins
KHKe Hu
Ke Hu
MGMargaret Goodall
Margaret Goodall
JMJane Mckeating
Jane Mckeating
Viruses initiate infection by attaching to molecules or receptors at the cell surface. Hepatitis C virus (HCV) enters cells via a multistep process involving tetraspanin CD81, scavenger receptor class B member I, and the tight junction proteins Claudin-1 and Occludin. CD81 and scavenger receptor class B member I interact with HCV-encoded glycoproteins, suggesting an initial role in mediating virus attachment. In contrast, there are minimal data supporting Claudin-1 association with HCV particles, raising questions as to its role in the virus internalization process. In the present study we demonstrate a relationship between receptor active Claudins and their association and organization with CD81 at the plasma membrane by fluorescence resonance energy transfer and stoichiometric imaging methodologies. Mutation of residues 32 and 48 in the Claudin-1 first extracellular loop ablates CD81 association and HCV receptor activity. Furthermore, mutation of the same residues in the receptor-inactive Claudin-7 molecule enabled CD81 complex formation and virus entry, demonstrating an essential role for Claudin-CD81 complexes in HCV infection. Importantly, Claudin-1 associated with CD81 at the basolateral membrane of polarized HepG2 cells, whereas tight junction-associated pools of Claudin-1 demonstrated a minimal association with CD81. In summary, we demonstrate an essential role for Claudin-CD81 complexes in HCV infection and their localization at the basolateral surface of polarized hepatoma cells, consistent with virus entry into the liver via the sinusoidal blood and association with basal expressed forms of the receptors.

15 May 2008 in Journal of Virology
Verified
Journal Article
Open access
PDF file
HHHelen J. Harris
Helen J. Harris
MFMichelle J. Farquhar
Michelle J. Farquhar
CMChristopher J. Mee
Christopher J. Mee
CDChristopher Davis
Christopher Davis
GRGary M. Reynolds
Gary M. Reynolds
JMJane Mckeating
Jane Mckeating
Hepatitis C virus (HCV) is an enveloped positive-stranded RNA hepatotropic virus. HCV pseudoparticles infect liver-derived cells, supporting a model in which liver-specific molecules define HCV internalization. Three host cell molecules have been reported to be important entry factors or receptors for HCV internalization: scavenger receptor BI, the tetraspanin CD81, and the tight junction protein claudin-1 (CLDN1). None of the receptors are uniquely expressed within the liver, leading us to hypothesize that their organization within hepatocytes may explain receptor activity. Since CD81 and CLDN1 act as coreceptors during late stages in the entry process, we investigated their association in a variety of cell lines and human liver tissue. Imaging techniques that take advantage of fluorescence resonance energy transfer (FRET) to study protein-protein interactions have been developed.Aequorea coerulescensgreen fluorescent protein- andDiscosomasp. red-monomer fluorescent protein-tagged forms of CD81 and CLDN1 colocalized, and FRET occurred between the tagged coreceptors at comparable frequencies in permissive and nonpermissive cells, consistent with the formation of coreceptor complexes. FRET occurred between antibodies specific for CD81 and CLDN1 bound to human liver tissue, suggesting the presence of coreceptor complexes in liver tissue. HCV infection and treatment of Huh-7.5 cells with recombinant HCV E1-E2 glycoproteins and anti-CD81 monoclonal antibody modulated homotypic (CD81-CD81) and heterotypic (CD81-CLDN1) coreceptor protein association(s) at specific cellular locations, suggesting distinct roles in the viral entry process.

26 March 2010 in Hepatology
Verified
Journal Article
Open access
PDF file
SKSophie E. Krieger
Sophie E. Krieger
MZMirjam B. Zeisel
Mirjam B. Zeisel
CDChristopher Davis
Christopher Davis
CTChristine Thumann
Christine Thumann
HHHelen J. Harris
Helen J. Harris
TBThomas Baumert
Thomas Baumert
The tight junction protein claudin‐1 (CLDN1) has been shown to be essential for hepatitis C virus (HCV) entry—the first step of viral infection. Due to the lack of neutralizing anti‐CLDN1 antibodies, the role of CLDN1 in the viral entry process is poorly understood. In this study, we produced antibodies directed against the human CLDN1 extracellular loops by genetic immunization and used these antibodies to investigate the mechanistic role of CLDN1 for HCV entry in an infectious HCV cell culture system and human hepatocytes. Antibodies specific for cell surface–expressed CLDN1 specifically inhibit HCV infection in a dose‐dependent manner. Antibodies specific for CLDN1, scavenger receptor B1, and CD81 show an additive neutralizing capacity compared with either agent used alone. Kinetic studies with anti‐CLDN1 and anti‐CD81 antibodies demonstrate that HCV interactions with both entry factors occur at a similar time in the internalization process. Anti‐CLDN1 antibodies inhibit the binding of envelope glycoprotein E2 to HCV permissive cell lines in the absence of detectable CLDN1‐E2 interaction. Using fluorescent‐labeled entry factors and fluorescence resonance energy transfer methodology, we demonstrate that anti‐CLDN1 antibodies inhibit CD81‐CLDN1 association. In contrast, CLDN1‐CLDN1 and CD81‐CD81 associations were not modulated. Taken together, our results demonstrate that antibodies targeting CLDN1 neutralize HCV infectivity by reducing E2 association with the cell surface and disrupting CD81‐CLDN1 interactions. Conclusion: These results further define the function of CLDN1 in the HCV entry process and highlight new antiviral strategies targeting E2‐CD81‐CLDN1 interactions. (HEPATOLOGY 2010.)

1 September 2010 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
IFIsabel Fofana
Isabel Fofana
SKSophie E. Krieger
Sophie E. Krieger
FGFritz Grunert
Fritz Grunert
SGSandra Glauben
Sandra Glauben
FXFei Xiao
Fei Xiao
TBThomas Baumert
Thomas Baumert

23 March 2015 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
LMLaurent Mailly
Laurent Mailly
FXFei Xiao
Fei Xiao
JLJoachim Lupberger
Joachim Lupberger
GWGarrick K Wilson
Garrick K Wilson
PAPhilippe Aubert
Philippe Aubert
TBThomas Baumert
Thomas Baumert
Hepatitis C virus (HCV) infection is a leading cause of liver cirrhosis and cancer1. Cell entry of HCV2 and other pathogens3,4,5 is mediated by tight junction (TJ) proteins, but successful therapeutic targeting of TJ proteins has not been reported yet. Using a human liver–chimeric mouse model6, we show that a monoclonal antibody specific for the TJ protein claudin-1 (ref. 7) eliminates chronic HCV infection without detectable toxicity. This antibody inhibits HCV entry, cell-cell transmission and virus-induced signaling events. Antibody treatment reduces the number of HCV-infected hepatocytes in vivo, highlighting the need for de novo infection by means of host entry factors to maintain chronic infection. In summary, we demonstrate that an antibody targeting a virus receptor can cure chronic viral infection and uncover TJ proteins as targets for antiviral therapy.